{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:16Z","timestamp":1786980256455,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,8,17]],"date-time":"2012-08-17T00:00:00Z","timestamp":1345161600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s00467-012-2222-9","type":"journal-article","created":{"date-parts":[[2012,8,16]],"date-time":"2012-08-16T01:15:37Z","timestamp":1345079737000},"page":"679-687","source":"Crossref","is-referenced-by-count":46,"title":["Renal complications of Fabry disease in children"],"prefix":"10.1007","volume":"28","author":[{"given":"Behzad","family":"Najafian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hopkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Svarstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,17]]},"reference":[{"key":"2222_CR1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1447-0756.1985.tb00045.x","volume":"11","author":"O Tsutsumi","year":"1985","unstructured":"Tsutsumi O, Sato M, Sato K, Mizuno M, Sakamoto S (1985) Early prenatal diagnosis of inborn error of metabolism: a case report of a fetus affected with Fabry\u2019s disease. Asia Oceania J Obstet Gynaecol 11:39\u201345","journal-title":"Asia Oceania J Obstet Gynaecol"},{"key":"2222_CR2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 64:550\u2013555","journal-title":"Pediatr Res"},{"key":"2222_CR3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79:31\u201340","journal-title":"Am J Hum Genet"},{"key":"2222_CR4","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","volume":"24","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, Sorensen SA, Wilcox WR, Desnick RJ (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24:2102\u20132111","journal-title":"Nephrol Dial Transplant"},{"key":"2222_CR5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/ndt\/12.1.221","volume":"12","author":"M Meroni","year":"1997","unstructured":"Meroni M, Spisni C, Tazzari S, Di Vito R, Stingone A, Bovan I, Torri Tarelli L, Sessa A (1997) Isolated glomerular proteinuria as the only clinical manifestation of Fabry\u2019s disease in an adult male. Nephrol Dial Transplant 12:221\u2013223","journal-title":"Nephrol Dial Transplant"},{"key":"2222_CR6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0272-6386(83)80047-X","volume":"2","author":"KJ Sheth","year":"1983","unstructured":"Sheth KJ, Roth DA, Adams MB (1983) Early renal failure in Fabry\u2019s disease. Am J Kidney Dis 2:651\u2013654","journal-title":"Am J Kidney Dis"},{"key":"2222_CR7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","volume":"81","author":"MH Branton","year":"2002","unstructured":"Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81:122\u2013138","journal-title":"Medicine (Baltimore)"},{"key":"2222_CR8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ndt\/gfp554","volume":"25","author":"A Ortiz","year":"2010","unstructured":"Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, Villalobos J, Vujkovac B, Waldek S, Wanner C, Warnock DG (2010) End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant 25:769\u2013775","journal-title":"Nephrol Dial Transplant"},{"key":"2222_CR9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1651-2227.2008.00700.x","volume":"97","author":"C Kampmann","year":"2008","unstructured":"Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M (2008) Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 97:463\u2013469","journal-title":"Acta Paediatr"},{"key":"2222_CR10","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ (2008) Fabry\u2019s disease. Lancet 372:1427\u20131435","journal-title":"Lancet"},{"key":"2222_CR11","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1053\/j.ajkd.2005.01.036","volume":"45","author":"M Cybulla","year":"2005","unstructured":"Cybulla M, Schaefer E, Wendt S, Ling H, Krober SM, Hovelborn U, Schandelmaier S, Rohrbach R, Neumann HP (2005) Chronic renal failure and proteinuria in adulthood: Fabry disease predominantly affecting the kidneys. Am J Kidney Dis 45:e82\u201389","journal-title":"Am J Kidney Dis"},{"key":"2222_CR12","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","volume":"12","author":"O Lidove","year":"2010","unstructured":"Lidove O, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Mehta A (2010) Effects of enzyme replacement therapy in Fabry disease\u2013a comprehensive review of the medical literature. Genet Med 12:668\u2013679","journal-title":"Genet Med"},{"key":"2222_CR13","unstructured":"(2010) Fabry Registry minimum recommended schedule of assessment. http:\/\/www.fabrazyme.com\/global\/freg schedule of assessments.pdf"},{"key":"2222_CR14","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","volume":"118","author":"M Ries","year":"2006","unstructured":"Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, Pastores G, Lien YH, Kampmann C, Brady RO, Beck M, Schiffmann R (2006) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118:924\u2013932","journal-title":"Pediatrics"},{"key":"2222_CR15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1399-0004.2011.01671.x","volume":"81","author":"U Ramaswami","year":"2011","unstructured":"Ramaswami U, Parini R, Pintos-Morell G, Kalkum G, Kampmann C, Beck M, Investigators FOS (2011) Fabry disease in children and response to enzyme replacement therapy: results from the Fabry outcome survey. Clin Genet 81:485\u2013490","journal-title":"Clin Genet"},{"key":"2222_CR16","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","volume":"152","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Tylki-Szymanska A, Guffon N, Lien YH, Tsimaratos M, Vellodi A, Germain DP (2008) Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 152:563\u2013570","journal-title":"J Pediatr"},{"key":"2222_CR17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","volume":"51","author":"C Tondel","year":"2008","unstructured":"T\u00f8ndel C, Bostad L, Hirth A, Svarstad E (2008) Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 51:767\u2013776","journal-title":"Am J Kidney Dis"},{"key":"2222_CR18","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","volume":"79","author":"B Najafian","year":"2011","unstructured":"Najafian B, Svarstad E, Bostad L, Gubler MC, T\u00f8ndel C, Whitley C, Mauer M (2011) Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int 79:663\u2013670","journal-title":"Kidney Int"},{"key":"2222_CR19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","volume":"30","author":"AC Vedder","year":"2007","unstructured":"Vedder AC, Linthorst GE, van Breemen MJ, Groener JE, Bemelman FJ, Strijland A, Mannens MM, Aerts JM, Hollak CE (2007) The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30:68\u201378","journal-title":"J Inherit Metab Dis"},{"key":"2222_CR20","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105:2812\u20132817","journal-title":"Proc Natl Acad Sci USA"},{"key":"2222_CR21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehp387","volume":"31","author":"N Brakch","year":"2010","unstructured":"Brakch N, Dormond O, Bekri S, Golshayan D, Correvon M, Mazzolai L, Steinmann B, Barbey F (2010) Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur Heart J 31:67\u201376","journal-title":"Eur Heart J"},{"key":"2222_CR22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2215\/CJN.06090809","volume":"5","author":"R Schiffmann","year":"2010","unstructured":"Schiffmann R, Waldek S, Benigni A, Auray-Blais C (2010) Biomarkers of Fabry disease nephropathy. Clin J Am Soc Nephrol 5:360\u2013364","journal-title":"Clin J Am Soc Nephrol"},{"key":"2222_CR23","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547\u20131557","journal-title":"J Am Soc Nephrol"},{"key":"2222_CR24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5414\/CNP71118","volume":"71","author":"KM Aakre","year":"2009","unstructured":"Aakre KM, T\u00f8ndel C, Brun A, Svarstad E (2009) The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function. Clin Nephrol 71:118\u2013124","journal-title":"Clin Nephrol"},{"key":"2222_CR25","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2215\/CJN.01640309","volume":"4","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Work DF (2009) Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 4:1832\u20131843","journal-title":"Clin J Am Soc Nephrol"},{"key":"2222_CR26","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/ndt\/gfp658","volume":"25","author":"C Tondel","year":"2010","unstructured":"T\u00f8ndel C, Ramaswami U, Aakre KM, Wijburg F, Bouwman M, Svarstad E (2010) Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate. Nephrol Dial Transplant 25:1507\u20131513","journal-title":"Nephrol Dial Transplant"},{"key":"2222_CR27","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","volume":"20","author":"M West","year":"2009","unstructured":"West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M, Barshop BA, Rhead W, Mensah R, Ries M, Schiffmann R (2009) Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 20:1132\u20131139","journal-title":"J Am Soc Nephrol"},{"key":"2222_CR28","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1373\/clinchem.2005.051557","volume":"51","author":"A Grubb","year":"2005","unstructured":"Grubb A, Nyman U, Bjork J, Lindstrom V, Rippe B, Sterner G, Christensson A (2005) Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem 51:1420\u20131431","journal-title":"Clin Chem"},{"key":"2222_CR29","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/ki.2010.321","volume":"78","author":"BO Eriksen","year":"2010","unstructured":"Eriksen BO, Mathisen UD, Melsom T, Ingebretsen OC, Jenssen TG, Njolstad I, Solbu MD, Toft I (2010) Cystatin C is not a better estimator of GFR than plasma creatinine in the general population. Kidney Int 78:1305\u20131311","journal-title":"Kidney Int"},{"key":"2222_CR30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/ki.2009.398","volume":"77","author":"GJ Schwartz","year":"2010","unstructured":"Schwartz GJ, Abraham AG, Furth SL, Warady BA, Munoz A (2010) Optimizing iohexol plasma disappearance curves to measure the glomerular filtration rate in children with chronic kidney disease. Kidney Int 77:65\u201371","journal-title":"Kidney Int"},{"key":"2222_CR31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1258\/acb.2009.009007","volume":"46","author":"EJ Lamb","year":"2009","unstructured":"Lamb EJ, MacKenzie F, Stevens PE (2009) How should proteinuria be detected and measured? Ann Clin Biochem 46:205\u2013217","journal-title":"Ann Clin Biochem"},{"key":"2222_CR32","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00467-006-0110-x","volume":"21","author":"P Wornell","year":"2006","unstructured":"Wornell P, Dyack S, Crocker J, Yu W, Acott P (2006) Fabry disease and nephrogenic diabetes insipidus. Pediatr Nephrol 21:1185\u20131188","journal-title":"Pediatr Nephrol"},{"key":"2222_CR33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","volume":"139","author":"TH Jafar","year":"2003","unstructured":"Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS (2003) Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139:244\u2013252","journal-title":"Ann Intern Med"},{"key":"2222_CR34","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.105.538132","volume":"112","author":"J Arnlov","year":"2005","unstructured":"Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D\u2019Agostino RB, Vasan RS (2005) Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112:969\u2013975","journal-title":"Circulation"},{"key":"2222_CR35","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","volume":"18","author":"H Tahir","year":"2007","unstructured":"Tahir H, Jackson LL, Warnock DG (2007) Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 18:2609\u20132617","journal-title":"J Am Soc Nephrol"},{"key":"2222_CR36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000168482","volume":"29","author":"S Feriozzi","year":"2009","unstructured":"Feriozzi S, Schwarting A, Sunder-Plassmann G, West M, Cybulla M (2009) Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am J Nephrol 29:353\u2013361","journal-title":"Am J Nephrol"},{"key":"2222_CR37","doi-asserted-by":"crossref","first-page":"c43","DOI":"10.1159\/000320903","volume":"118","author":"G Jain","year":"2011","unstructured":"Jain G, Warnock DG (2011) Blood pressure, proteinuria and nephropathy in Fabry disease. Nephron Clin Pract 118:c43\u201348","journal-title":"Nephron Clin Pract"},{"key":"2222_CR38","first-page":"123","volume":"27","author":"PL Poulsen","year":"2001","unstructured":"Poulsen PL, Ebbehoj E, Nosadini R, Fioretto P, Deferrari G, Crepaldi G, Mogensen CE (2001) Early ACE-i intervention in microalbuminuric patients with type 1 diabetes: effects on albumin excretion, 24 h ambulatory blood pressure, and renal function. Diabetes Metab 27:123\u2013128","journal-title":"Diabetes Metab"},{"key":"2222_CR39","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","volume":"354","author":"P Ruggenenti","year":"1999","unstructured":"Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359\u2013364","journal-title":"Lancet"},{"key":"2222_CR40","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","volume":"11","author":"S Waldek","year":"2009","unstructured":"Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 11:790\u2013796","journal-title":"Genet Med"},{"key":"2222_CR41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF00860748","volume":"9","author":"AB Bohlin","year":"1995","unstructured":"Bohlin AB, Edstrom S, Almgren B, Jaremko G, Jorulf H (1995) Renal biopsy in children: indications, technique and efficacy in 119 consecutive cases. Pediatr Nephrol 9:201\u2013203","journal-title":"Pediatr Nephrol"},{"key":"2222_CR42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93:112\u2013128","journal-title":"Mol Genet Metab"},{"key":"2222_CR43","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2165\/11318300-000000000-00000","volume":"69","author":"RM Schaefer","year":"2009","unstructured":"Schaefer RM, Tylki-Szymanska A, Hilz MJ (2009) Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs 69:2179\u20132205","journal-title":"Drugs"},{"key":"2222_CR44","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","volume":"5","author":"C Wanner","year":"2010","unstructured":"Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, Serra AL, Marodi L, Mignani R, Cianciaruso B, Vujkovac B, Lemay R, Beitner-Johnson D, Waldek S, Warnock DG (2010) Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol 5:2220\u20132228","journal-title":"Clin J Am Soc Nephrol"},{"key":"2222_CR45","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/ndt\/gfp434","volume":"25","author":"F Hussain","year":"2010","unstructured":"Hussain F, Mallik M, Marks SD, Watson AR (2010) Renal biopsies in children: current practice and audit of outcomes. Nephrol Dial Transplant 25:485\u2013489","journal-title":"Nephrol Dial Transplant"},{"key":"2222_CR46","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","volume":"21","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21:345\u2013354","journal-title":"Nephrol Dial Transplant"},{"key":"2222_CR47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77\u201386","journal-title":"Ann Intern Med"},{"key":"2222_CR48","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00428-007-0468-6","volume":"451","author":"H Askari","year":"2007","unstructured":"Askari H, Kaneski CR, Semino-Mora C, Desai P, Ang A, Kleiner DE, Perlee LT, Quezado M, Spollen LE, Wustman BA, Schiffmann R (2007) Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch 451:823\u2013834","journal-title":"Virchows Arch"},{"key":"2222_CR49","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","volume":"13","author":"MC Gubler","year":"1978","unstructured":"Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R (1978) Early renal changes in hemizygous and heterozygous patients with Fabry\u2019s disease. Kidney Int 13:223\u2013235","journal-title":"Kidney Int"},{"key":"2222_CR50","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/ndt\/gfp528","volume":"25","author":"AB Fogo","year":"2010","unstructured":"Fogo AB, Bostad L, Svarstad E, Cook WJ, Moll S, Barbey F, Geldenhuys L, West M, Ferluga D, Vujkovac B, Howie AJ, Burns A, Reeve R, Waldek S, Noel LH, Grunfeld JP, Valbuena C, Oliveira JP, Muller J, Breunig F, Zhang X, Warnock DG (2010) Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 25:2168\u20132177","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 2","key":"2222_CR51","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1097\/01.ASN.0000016684.07368.75","volume":"13","author":"J Alroy","year":"2002","unstructured":"Alroy J, Sabnis S, Kopp JB (2002) Renal pathology in Fabry disease. J Am Soc Nephrol 13(Suppl 2):S134\u2013138","journal-title":"J Am Soc Nephrol"},{"key":"2222_CR52","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000183006","volume":"34","author":"E Rosenmann","year":"1983","unstructured":"Rosenmann E, Kobrin I, Cohen T (1983) Kidney involvement in systemic lupus erythematosus and Fabry\u2019s disease. Nephron 34:180\u2013184","journal-title":"Nephron"},{"key":"2222_CR53","first-page":"655","volume":"37","author":"Y Hiraizumi","year":"1995","unstructured":"Hiraizumi Y, Kanoh M, Shigematsu H, Yamashina M, Kondo T (1995) A case of Fabry\u2019s disease with granulomatous interstitial nephritis. Nippon Jinzo Gakkai Shi 37:655\u2013661","journal-title":"Nippon Jinzo Gakkai Shi"},{"key":"2222_CR54","first-page":"73","volume":"55","author":"HK Singh","year":"2001","unstructured":"Singh HK, Nickeleit V, Kriegsmann J, Harris AA, Jennette JC, Mihatsch MJ (2001) Coexistence of Fabry\u2019s disease and necrotizing and crescentic glomerulonephritis. Clin Nephrol 55:73\u201379","journal-title":"Clin Nephrol"},{"key":"2222_CR55","first-page":"71","volume":"47","author":"O Kawamura","year":"1997","unstructured":"Kawamura O, Sakuraba H, Itoh K, Suzuki Y, Doi M, Kuwabara H, Oshima S, Abe S, Warabi H, Yoshizawa N (1997) Subclinical Fabry\u2019s disease occurring in the context of IgA nephropathy. Clin Nephrol 47:71\u201375","journal-title":"Clin Nephrol"},{"key":"2222_CR56","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","volume":"69","author":"F Breunig","year":"2006","unstructured":"Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69:1216\u20131221","journal-title":"Kidney Int"},{"key":"2222_CR57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-6-69","volume":"6","author":"BE Smid","year":"2011","unstructured":"Smid BE, Rombach SM, Aerts JM, Kuiper S, Mirzaian M, Overkleeft HS, Poorthuis BJ, Hollak CE, Groener JE, Linthorst GE (2011) Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. Orphanet J Rare Dis 6:69","journal-title":"Orphanet J Rare Dis"},{"key":"2222_CR58","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","volume":"68","author":"CM Eng","year":"2001","unstructured":"Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, Brodie S, Stacy CB, Mehta D, Parsons R, Norton K, O\u2019Callaghan M, Desnick RJ (2001) A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711\u2013722","journal-title":"Am J Hum Genet"},{"key":"2222_CR59","first-page":"iii25","volume":"3","author":"C Tondel","year":"2010","unstructured":"T\u00f8ndel C, Bostad L, Svarstad E (2010) 5 years follow-uprenal biopsies in paediatric and adult Fabry patients on enzyme replacement therapy. NDT Plus 3:iii25","journal-title":"NDT Plus"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-012-2222-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-012-2222-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-012-2222-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T18:13:45Z","timestamp":1562091225000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-012-2222-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,17]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["2222"],"URL":"https:\/\/doi.org\/10.1007\/s00467-012-2222-9","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,17]]}}}